Author : Mochammad Thaha, dr.,PhD.Sp.PD, K-GH, FINASIM

Abstact :

Abstract. Aim: Cardiovascular disease is the main cause of mortality in chronic kidney disease patients. Moreover, uremic patients are in a pro-oxidant state and show an increase in asymmetric dimethylarginine (ADMA) levels due to inhibition of the enzyme dimethylarginine dimethylaminohydrolase (DDAH).

Asymmetric dimethylarginine per se seems responsible for a 52o/o increase in the risk of death and for a 34% increase in the risk of cardiovascular events in dialysis patients. N-aceflcysteine (NAC) is a thiol molecule that has direct and indirect antioxidant effects which decrease reactive oxidant species and increase the bioavailability of the DDAH enzyme. The aim of the current study was to determine the effect of intravenous NAC on plasma ADMA level when administered during hernodialysis in end-stage renal disease (ESRD) patients. Materials and methods: 40 pafients with ESRD were randomized to receive a 4-hour intravenous infusion of NAC or placebo during a 4-hour hemodialysis session. There were 3 diabetic patients (15%) in the ffeatment group and 6 patients in the control group. Plasma ADMA levels were measured before and immediately after hemodialysis. Hemodynamic parameters, including pulse pressure, were also measured. The paired t-test was used to compare the difference of ADMA levels before and after hemodialysis in each group, while the independent t-test was used to compare the difference of ADMA levels between the groups. Results:
Compared with the pre-dialysis condition, there was a decrease of ADMA level in the control group (1.1253 + 0.1797 M to 0.8676 + 0.1449 M) (p < 0.001), and in the NAC group (1.1522 r 0.1737 M to 0.7844 +
0.1586 M) (p < 0.001). Compared with hemodialysis alone, NAC had a greater lowering effect on the ADMA level (21.3 vs. 31.9%, p<0.05). Conclusion: N-acetylcysteine (NAC) administered intravenously during hemodialysis reduced asymmetric dimethyl-arginine (ADMA) levels more significantly than hemodialysis alone.